Progenics Pharmaceuticals
(PGNX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2010 | 12-2009 | 09-2009 | 06-2009 | 03-2009 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -18,583 | -30,612 | -29,973 | -16,959 | -1,788 |
| Depreciation Amortization | 877 | 5,967 | 4,516 | 3,252 | 1,502 |
| Accounts receivable | -280 | -6,185 | 640 | 610 | 645 |
| Other Working Capital | 2,453 | -38,247 | -22,909 | -19,686 | -18,379 |
| Other Operating Activity | 2,882 | 19,268 | 9,598 | 6,541 | 3,499 |
| Operating Cash Flow | $-12,651 | $-49,809 | $-38,128 | $-26,242 | $-14,521 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 1,700 | 80,233 | 80,233 | 62,757 | 19,759 |
| PPE Investments | -12 | -901 | -836 | -724 | -597 |
| Other Investing Activity | 0 | 320 | 170 | 0 | 0 |
| Investing Cash Flow | $1,688 | $79,652 | $79,567 | $62,033 | $19,162 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 1,145 | 4,874 | 3,821 | 2,652 | 1,461 |
| Financing Cash Flow | $1,145 | $4,874 | $3,821 | $2,652 | $1,461 |
| Beginning Cash Position | 90,903 | 56,186 | 56,186 | 56,186 | 56,186 |
| End Cash Position | 81,085 | 90,903 | 101,446 | 94,629 | 62,288 |
| Net Cash Flow | $-9,818 | $34,717 | $45,260 | $38,443 | $6,102 |
| Free Cash Flow | |||||
| Operating Cash Flow | -12,651 | -49,809 | -38,128 | -26,242 | -14,521 |
| Capital Expenditure | -12 | -901 | -836 | -724 | -597 |
| Free Cash Flow | -12,663 | -50,710 | -38,964 | -26,966 | -15,118 |